Description

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety and Tolerability of AVP-786 (deuterated [d6]-dextromethorphan hydrobromide [d6- DM]/quinidine sulfate [Q]) for the Treatment of Agitation in Patients with Dementia of the Alzheimer’s Type

This is a clinical research study for agitation in Alzheimer’s disease. Are you caring for a loved one with agitation due to Alzheimer’s disease?

The TRIAD™ research study is currently evaluating an investigational medication to see if it may reduce symptoms of agitation due to Alzheimer’s disease. To be considered for this study, patients must:

  • Have moderate to severe agitation due to Alzheimer’s disease (e.g., screaming or cursing) or physical aggression (e.g., hitting or kicking)
  • Be between 50 and 90 years of age
  • Have a caregiver able to attend all study visits

This study will include study-related medical exams and assessment at no cost and potential compensation for time and travel. Certain qualified participants may have an opportunity to receive the investigational medication for an additional year, as part of an extension study.

For more details, please call (713) 873-5145 or (346) 266-8167.

Contact

Uzma Khalid ukhalid@bcm.eduPhone 1: (713) 873-5145 Phone 2: (346) 266-8167
IRB: h-41658

Status

Active

Created

Jun 26, 2018